Status:
COMPLETED
Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects
Lead Sponsor:
innoVactiv Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
It is already known from animal studies that the study drug can improve mucosal immunity as shown by increased serum and mucosal IgA secretion. This study will evaluate the safety of an oral intake of...
Eligibility Criteria
Inclusion
- Men or women aged 18 - 60
- In good health
- BMI between 20 and 30 kg/m2
- Non-smoking
Exclusion
- Allergic to study drug
- Use of immune-modulating drugs
- Uncontrolled hypertension (Systolic \> 140 or diastolic \> 90)
- Women of childbearing age not using proper contraception, that is pregnant or breastfeeding
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00906438
Start Date
May 1 2009
End Date
October 1 2009
Last Update
October 29 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)
Québec, Quebec, Canada, G1K 7P4